Morgan Stanley Cuts Gilead Price Target After Q1 Earnings Beat
Morgan Stanley lowered its Gilead price target to $168 from $175 but kept an Overweight rating, while Truist raised its target to $157 after the company beat Q1 estimates and raised FY26 revenue guidance.
Morgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $168 from $175 following the company's first-quarter earnings report, while reiterating an Overweight rating. The adjustment reflects updated model assumptions after Gilead reported results that exceeded expectations. Separately, Truist raised its price target to $157 from $155, maintaining a Buy rating, citing stronger-than-anticipated revenue and earnings in Q1 as well as an upward revision to FY26 revenue guidance.
For traders, analyst rating changes can influence near-term sentiment on GILD stock. The divergence between Morgan Stanley's target cut and Truist's target hike highlights differing views on valuation, though both firms remain bullish. Gilead's performance was driven by strength in its core HIV and oncology portfolios, which are key revenue drivers. Investors tracking biotech stocks should monitor upcoming pipeline catalysts and clinical trial readouts that could further impact the stock. For current pricing on GILD and other biotech equities, check NowPrice's equities page.
Looking ahead, market participants will focus on Gilead's ability to sustain revenue growth amid competitive pressures in HIV and oncology. Key events include potential FDA approvals and updates on the company's pipeline, including its cell therapy and antibody-drug conjugate programs. The next quarterly report will provide further clarity on whether the positive momentum can be maintained. Analysts will also watch for any changes to full-year guidance as the year progresses.